NCT00475917终止1 期
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Exelixis
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Safety and tolerability of XL844 as a single agent and in combination with gemcitabine when administered orally to subjects with advanced malignancies
研究概览
简要总结
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject has a histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival.
- •The subject has disease that is assessable by tumor marker, physical, or radiologic means.
- •The subject is ≥18 years old.
- •The subject has an ECOG (Eastern Cooperative Oncology Group) performance status of ≤
- •The subject has adequate organ and marrow function.
- •The subject has the capability of understanding the informed consent document and has signed the informed consent document.
- •Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.
- •Female subjects of childbearing potential must have a negative pregnancy test at screening.
- •If a subject has received more than three prior regimens of cytotoxic chemotherapy, more than two biologic regimens, or more than 3000 cGy to >25% of his or her bone marrow, the investigator must discuss with the sponsor regarding subject suitability before enrollment.
- •The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥5 years ago, and has had no evidence of disease for 5 years prior to screening for this study).
排除标准
- •The subject has received anticancer treatment (eg, chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agent, or hormones) within 14 days prior to the first dose of study drug.
- •The subject has not recovered to Grade ≤1 from adverse events (AEs) due to investigational agents or other medications administered more than 30 days prior to the first dose of study drug.
- •The subject has received radiation to >25% of his or her bone marrow within 30 days of XL844 treatment.
- •The subject has a primary brain tumor or known brain metastases.
- •The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •The subject is pregnant or breastfeeding.
- •The subject is known to be positive for the human immunodeficiency virus (HIV).
- •The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
- •The subject has a known allergy or hypersensitivity to any of the components of the XL844 formulation or gemcitabine.
研究组 & 干预措施
1
Experimental
干预措施: XL844 (Drug)
1
Experimental
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Safety and tolerability of XL844 as a single agent and in combination with gemcitabine when administered orally to subjects with advanced malignancies
时间窗: Assessed at each visit/periodic visits
Evaluate plasma pharmacokinetics and estimate renal elimination of XL844 as a single agent and in combination with gemcitabine
时间窗: Assessed at periodic visits
Determine the Combination maximum tolerated dose and dose-limiting toxicities for XL844 alone and in combination with gemcitabine
时间窗: Assessed at periodic visits
次要结局
- (Exploratory:) Assess tumor response after repeated administration of XL844 in combination with gemcitabine in subjects with advanced malignancies(Assessed at periodic visits)
- Pharmacodynamic correlates of XL844 activity in tumor tissue(Assessed at periodic visits)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Safety Study of XL844 in Subjects With Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT00234481Exelixis
撤回
1 期
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsNon-small-cell Lung CancerCancerBreast CancerNCT00704392Exelixis
终止
1 期
Safety Study of XL999 in Adults With Non-Small-Cell Lung CancerNon-Small-Cell Lung CancerNCT00491699Symphony Evolution, Inc.2
已完成
1 期
Single-dose and Multiple-dose X842 Phase 1 StudyHealthy VolunteersNCT04293965Jiangsu Sinorda Biomedicine Co., Ltd80
已完成
1 期
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsEndometrial CarcinomaOvarian CarcinomaCancerNon-Small Cell Lung CancerNCT00756847Sanofi52